证券代码：002644 证券简称：佛慈制药 兰州佛慈制药股份有限公司 投资者关系活动记录表 答：公司产品 1931 年开始出口，目前已出口至美国、加拿 大、澳大利亚、日本、泰国、印尼、香港等 32 个国家和地区， 公司海外产品注册数达 1442 个，在国外认证数量、海外商标注 册、出口覆盖范围及品种数方面长期居于行业领先地位。海外市 场是公司未来重点培育的大市场之一，公司将持续深化国际化战 略布局，依托佛慈出口优势，加大对海外市场的建设投入，推进 产品国际注册与合规认证，通过品牌共建、渠道共享强化推广， 不断扩大海外市场份额，打造更具国际影响力的中医药品牌。 4.公司库存水平如何？ 答：公司目前存货水平处于合理范围内，周转率符合行业特 点和平均水平。公司也将密切关注产能和市场需求情况，总体保 持产销平衡，合理控制存货规模。 5.公司 2025 年投资科近泰基公司的背景和原因？ 答：公司经过充分的前期调研和论证，2025 年 10 月投资 2,000 万元参与了科近泰基新技术有限公司的增资扩股，布局放 射性同位素药物赛道。科近泰基公司是中国科学院近物所下设的 全资子公司，未来科近泰基公司主要业务为协同中国科学院 ...

Core Insights - The company plans to continue its strategy of developing major products and markets through 2026, focusing on core products to drive overall sales growth [2] Product Strategy - The company aims to consolidate and enhance the market share of its traditional concentrated pill products, particularly the Liuwei Dihuang Wan series [2] - There will be an increased focus on the sales of exclusive products such as the Shenrong Guben Huan Shao Wan and the Compound Huangqi Jianpi Oral Liquid, as well as other high-demand products like Erchen Wan, Angong Niuhuang Wan, Bazhen Wan, and Anshen Buxin Wan [2] Market Development - The company is concentrating on its base markets in Shaanxi and Gansu while strengthening its national market layout and channel development [2] - There is a specific emphasis on expanding into the South China market and international markets to gradually enhance market competitiveness and increase market share and product sales [2]

Core Viewpoint - The company, Foci Pharmaceutical, announced on August 28 that its leading products in sales for the first half of 2025 will include traditional Chinese medicine products such as Liuwei Dihuang Wan, Erchen Wan, Xiaoyao Wan, Guipi Wan, Bazhen Wan, and others, indicating a strong market presence and strategic focus on these items [1] Product Strategy - The company plans to continue its strategy of developing major products, aiming to consolidate and enhance the market share of traditional concentrated pill products like Liuwei Dihuang Wan series [1] - There is a particular emphasis on increasing sales of unique products such as Shenrong Gudan Wan and Fufang Huangqi Jianpi Oral Liquid, as well as high-demand products like Erchen Wan, Angong Niuhuang Wan, Bazhen Wan, and Anshen Buxin Wan [1]

Financial Performance - In the first half of 2025, the company's revenue reached 3,010.46 million CNY, with a net profit attributable to shareholders of 42.9 million CNY, and a net cash flow from operating activities of 1,788.09 million CNY, achieving a year-on-year growth of 364.33% [2][4] - The overall gross margin for the first half of 2025 increased to 39.93%, up by 5.32% compared to the same period last year [3][7] Sales Channels and Market Strategy - The company maintained over 60% sales from commercial chains, approximately 20% from medical channels, and around 20% from online and other channels, with overall sales performance remaining stable compared to the previous year [4] - The company is leveraging e-commerce platforms like JD and Tmall to enhance market share and develop potential markets [4] Product Development and Innovation - The company is focusing on the secondary development of four unique products, including the Ren Shen Gu Ben Wan and Fu Fang Huang Qi Jian Pi Oral Liquid, aiming to enhance their market competitiveness through technological upgrades [6] - Major products with strong sales in the first half of 2025 include Liu Wei Di Huang Wan, Er Chen Wan, and An Gong Niu Huang Wan, with plans to continue promoting these key products [5] International Expansion - The company has exported products to 32 countries and regions, including the USA, Canada, and Australia, and has achieved significant international certifications, including TGA and PIC/S [8] - Future plans include increasing international market share through brand collaboration and channel sharing [8] Cost Management and Future Planning - The decrease in sales expenses is attributed to a decline in revenue and effective cost control measures implemented by the company [8] - The company is actively developing its "14th Five-Year Plan," focusing on marketing breakthroughs, brand building, and innovation in research and development [8]

Financial Performance - In 2024, the company achieved operating revenue of 98,022.54 million CNY, with a net profit attributable to shareholders of 6,006.98 million CNY, reflecting a decline due to economic conditions, healthcare policy changes, and intensified industry competition [2][3] - In Q1 2025, the company reported operating revenue of 21,612.47 million CNY, a year-on-year decrease of 21.22%, while net profit attributable to shareholders increased by 5.41% to 1,938.16 million CNY [3] - The net cash flow from operating activities in Q1 2025 was 811.04 million CNY, showing a significant year-on-year growth of 150.46% [3] Product Sales and Strategy - The top-selling products in 2024 included Liuwei Dihuang Wan, Xiaoyao Wan, and others, with the top ten products accounting for nearly 50% of total revenue [3] - The company plans to continue developing major products and enhance market share for traditional concentrated pill products [3] Cost Management and Profitability - The increase in gross and net profit margins in Q1 2025 was attributed to optimized marketing channel management, diversified sales strategies, and a decrease in raw material costs [3] - The decline in sales expense ratio in 2024 and Q1 2025 was primarily due to a decrease in operating revenue and effective cost control measures [4] Market Expansion and Subsidiary Management - The company aims to strengthen its presence in traditional markets while expanding into Southern China and international markets [4] - The subsidiary Longnan Foci was dissolved due to changes in market conditions and lack of business operations, with future plans focusing on core business efficiency [5] Strategic Planning and Future Outlook - The company is currently developing its "14th Five-Year" strategic plan, focusing on marketing, R&D innovation, digital transformation, and management improvement [5] - There are plans for potential mergers and acquisitions aimed at enhancing market channels and product development [5] - A shareholder dividend plan for 2024-2026 has been established to ensure reasonable returns to investors [5]